Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease
Running, not enrolling · Phase 4
Conditions studied: Peyronie Disease, Sexual Dysfunctions, Psychological, Genital Diseases, Male
In brief
The purpose of this study is to learn about the safety and side effects of intralesional collagenase clostridium histolyticum (CCH) injected into the Peyronies Disease (PD) plaque after receiving prior treatment with intralesional Platelet Rich Plasma (PRP) injections.
Key facts
- Study ID
- NCT05777031
- Run by
- University of Miami
- People needed
- 12
- Starts
- 2023-10-02
- Expected to finish
- 2027-01-15
- Last updated by the study team
- 2026-06-04
Who can join
Age: 18 and older, up to 75. Sex: male. Healthy volunteers: not accepted.
You may qualify if…
- Be able to provide written informed consent
- Have a diagnosis of PD with evidence of stable disease as determined by the investigator
- Patient must have palpable penile plaque
- Penile curvature deformity of >30° to <90°
- Agree to comply with all study related tests/procedures.
- Prior intralesional platelet rich plasma treatment within the past 18 months and desire secondary treatment of penile curvature
You may not qualify if…
- Previous penile surgery of any kind (except circumcision and condyloma removal), such as penile lengthening, penile cancer surgery, penile plication, grafting, penile prosthesis.
- Previous intralesional injection therapy with CCH for PD within six months. Patients with failed therapy greater than six months ago may be included.
- Previous history of priapism or penile fracture
- PD characterized by a ventral plaque
- Severe erectile dysfunction as characterized with an IIEF score ≤ 12
- Hour-glass deformity
- Unwilling to participate
- Medically unfit for sexual intercourse as deemed by the principal investigator
- Patients scheduled to undergo an elective medical procedure during the investigation timeframe that will interfere with autologous PRP injection therapy.
- Have a serious comorbid illness/condition/behavior that, in the opinion of the investigator, may compromise the safety or compliance of the subject or preclude successful completion of the study.
Where it is running
- University of Miami - Desai Sethi Urology Institute — Miami, Florida, United States
- University of Miami — Miami, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.